Certain bridged 4-phenyl-2-aminomethylimidazoles; new dopamine receptor subtype specific ligands
CA 2213197 C · Owner: Neurogen Corporation · Inventors: Yuan, Jun; Thurkauf, Andrew
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Disclosed are compounds encompassed by general formula (I) wherein, A , represents ethenylene, or A represents -X-CH2-; where X is carbon or oxygen provided that when X is oxygen, the oxygen is adjacent the 6-membered ring; R1, R2, R3 and R4 are inorganic or organic substituents; and R5 and R6 are optionally substituted organic substituents; or NR5R6 represents a carbocyclic or heterocyclic six-membered ring optionally substituted with various organic or inorganic groups, which compounds can be used in the treatment of neuropsychological disorders.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 14, 1996 and granted August 7, 2001. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 14, 2016.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 14, 2018.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.